We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Group K Diagnostics Demonstrates KromaHealth Kit that Enables Lab-Quality Results at Point-of-Care

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Image: KromaHealth Kit from Group K Diagnostics (Photo courtesy of Group K Diagnostics)
Image: KromaHealth Kit from Group K Diagnostics (Photo courtesy of Group K Diagnostics)

Group K Diagnostics (GKD; Philadelphia, PA, USA) demonstrated its KromaHealth Kit that enables point-of-care testing and fast results across a suite of various diagnostics at AACC 2021.

Every year, the global laboratory medicine community comes together at AACC to collaborate and create system-wide changes that improve patient outcomes and enhance the quality of life for all. The exhibition provides a platform to connect with the industry leaders making ground-breaking advancements in laboratory medicine, including clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, and lab management.

At this year’s AACC, GKD demonstrated its KromaHealth Kit which consists of a single-platform, versatile, point-of-care device, known as KromaHealth, paired with a mobile application used to read the test results, known as KromaViewer. Depending on the test, a user needs to simply place a few drops of blood, serum or urine on the device's testing sites to induce a color change that is translated into a clear diagnosis through an image processing algorithm. The process is simple and can be done in the physician's office with results provided before the patient leaves the physician’s office. The device is for investigational use only and its performance characteristics have not been established

GKD is currently developing the GKD Analytics Manager which is a dashboard for health system operators and researchers to monitor testing operations and collect anonymized results to analyze population health, disease management and compliance. GKD is also developing the MyGKD app which gives patients the ability view and track test results over time on their mobile phones. With this convenient access to their diagnostics, patients can own their results and be engaged in the effectiveness of their care.

Related Links:
Group K Diagnostics

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay

Print article
ADLM

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.